NASDAQ:UPB Upstream Bio Q2 2026 Earnings Results & Report $2.00 -0.08 (-3.85%) Closing price 04:00 PM EasternExtended Trading$2.02 +0.02 (+0.75%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Upstream Bio beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 11, 2026. The company reported EPS of -$0.73 versus the -$0.7444 consensus estimate, while revenue of $773 thousand topped the $561 thousand estimate by $212.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 11, 2026TimeBefore Market OpensConference Call7:00 AM ET Upstream Bio EPS ResultsActual EPS-$0.73Consensus EPS -$0.7444Beat/MissBeat by +$0.0144One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersUpstream Bio Revenue ResultsActual Revenue$773 thousandExpected Revenue$561 thousandBeat/MissBeat by +$212.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Upstream Bio Q2 2026 Earnings FAQ Did Upstream Bio beat earnings estimates for Q2 2026? Upstream Bio (NASDAQ:UPB) reported earnings of -$0.73 per share for Q2 2026, beating the consensus estimate of -$0.7444. The report was announced on Tuesday, August 11, 2026. What was Upstream Bio's revenue for Q2 2026? Upstream Bio reported revenue of $773 thousand for Q2 2026, against a consensus estimate of $561 thousand. Upstream Bio Earnings HeadlinesHC Wainwright Increases Earnings Estimates for Upstream BioNovember 15, 2026 | americanbankingnews.comUpstream Bio (NASDAQ:UPB) Stock Gets Price Target Reduction from HC WainwrightNovember 14, 2026 | americanbankingnews.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 19 at 1:00 AM | Porter & Company (Ad)Upstream Bio, Inc. (UPB) - What Are Researchers Saying About This Stock?November 13, 2026 | americanbankingnews.comUpstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued ProgressNovember 10, 2026 | globenewswire.comUpstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly DosingSeptember 8, 2026 | quiverquant.comQSee More Upstream Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email. Email Address About Upstream BioUpstream Bio (NASDAQ:UPB) is a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases. The company is based in Waltham, Massachusetts, and its research focuses on pathways involved in immune and inflammatory responses. Its lead product candidate, verekitug (UPB-101), is an antibody designed to block the receptor for thymic stromal lymphopoietin, a protein associated with inflammation. Upstream Bio is developing verekitug for conditions including asthma and chronic rhinosinusitis with nasal polyps. The company’s work is focused on drug development and clinical research; it does not have a marketed product portfolio.View Upstream Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.